ONE Championship Uses Brightcove to Stream Every Punch, Kick, Takedown, and Knockout on Its ‘ONE Super App’
ONE Championship (ONE), one of Asia’s largest global sports media properties, features a diverse array of content stacks, including live events, fight highlights, and reality television programming.
Since November 2020, ONE Championship’s content has been streaming on the Brightcove Inc. (NASDAQ: BCOV) video platform through the ONE Super App, cutting the company’s content management time in half and increasing video watch time by 300 percent.
The ONE Super App, available on the Apple App Store and Google Play, features ONE TV, which now includes a Brightcove-powered customizable experience with thematic playlists that continuously roll out videos, in-app alerts, and the latest news.
Fans access the ONE Super App to immerse themselves in the world’s greatest action across mixed martial arts, Muay Thai, kickboxing, and more.
“As our ONE Super App audience continues to scale globally, digital video will be indispensable to our long-term strategy,” said Jonathan Wong, Head of Product at ONE Championship. “When seeking a platform partner, Brightcove stood out for its flexibility, scalability, and video quality, all of which are critical as we evolve. With Brightcove, we are confident we can continue to share stories that ignite the world with hope, strength, dreams, and inspiration.”
The ONE Super App promotes fan engagement with athletes and fellow fans through mini-games and other interactions. Brightcove’s analytics yield valuable insights from data on devices, destinations, geography, and content popularity, making it easy for ONE Championship to optimize its operations.
“With ONE and Brightcove, martial arts fans can keep the excitement going wherever they are in the world and whenever they have a moment to engage with athletes, peers, and federations,” said Simon Naylor, Senior Vice President, Asia Pacific, Brightcove. “We’re committed to helping businesses like ONE Championship simply and cost-effectively monetize these experiences. We look forward to even more victories with our terrific new partner.”
About ONE Championship
ONE Championship (ONE) is the largest global sports media property in Asian history. Headquartered in Singapore, ONE is the world’s largest martial arts organization, hosting bouts across all styles of martial arts such as mixed martial arts, Muay Thai, kickboxing, and more. ONE hosts the biggest sports entertainment events across Asia, featuring some of the world’s best martial artists and World Champions on the largest global media broadcast in Asia. In addition to its digital platforms, ONE Championship broadcasts across 150+ countries with some of the largest global free-to-air and digital broadcasters, including Star Sports, Tencent, TV5, Astro, ClaroSports, Startimes, Fox Sports, Thairath TV, Turner Sports, Skynet, Mediacorp, Great Sports, Mediaset Italia, ProSiebenSat.1, Dubai Sports, and more.
About Brightcove
When video is done right, it can have a powerful and lasting effect. Hearts open. Minds change. Creativity thrives. Since 2004, Brightcove has been helping customers discover and experience the incredible power of video through its award-winning technology, empowering organizations in more than 70 countries across the globe to touch audiences in bold and innovative ways.
Brightcove achieves this by developing technologies once thought impossible, providing customer support without parallel or excuses, and leveraging the expertise and resources of a global infrastructure. Video is the world’s most compelling, exciting medium. Visit www.brightcove.com for more information. Video That Means Business.™
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210531005027/en/
Contact information
Press Contacts
Brightcove
Meredith Duhaime
mduhaime@brightcove.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom